New hope for Tough-to-Treat leukemia: early trial tests drug combo
NCT ID NCT06429449
Summary
This early-stage study is testing whether adding the drug mitoxantrone to a standard leukemia treatment can help patients whose cancer has returned or stopped responding. It will enroll about 30 adults with a specific type of acute myeloid leukemia. The main goals are to find a safe dose and see if the new combination can reduce or eliminate cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.